GET DAILY SIGNALSPark Dental Partners (PARK) Analysts See +34% Upside to $28.50 Target
Key Takeaways
- The central $28.50 target is the arithmetic mean of two verified analyst price targets: Northland at $27 and Craig-Hallum at $30, both issued in August 2026.
- With the stock recently trading near $21.19, reaching $28.50 implies roughly 34% upside—a substantial move for a micro-cap company.
- The analyst target range is unusually narrow, from $27 to $30, and both firms rate the shares a Buy or Outperform.
- Supporting factors include a "solid" second quarter, growing revenue, and an asset-light dental resource organization (DRO) model.
- Key risks include a market capitalization near $100 million, very thin trading volume, negative earnings per share (EPS), and dependence on only two covering analysts.
- Investors can explore more context on Park Dental Partners' Major News, Today's Price Move, Forecast, and Earnings pages.
- For broader market signals across thousands of equities, explore Trending AI Robots.
Analyst Targets and Consensus View
Park Dental Partners, Inc. (PARK) operates as a Minnesota-based dental resource organization, offering administrative, staffing, facility, and equipment support to practices in Minnesota, Wisconsin, and Arizona. Coverage on this newly public micro-cap remains limited, yet two identifiable targets stand out from reputable firms.
Northland lifted its target to $27 from $21.50 on August 13, 2026, keeping an Outperform rating after describing the second quarter as "solid." The following day, Craig-Hallum analyst Matthew Hewitt moved his target to $30 from $24 while maintaining a Buy rating and pointing to a strong quarter. The simple average of these two targets lands at $28.50, with the range tightly clustered between $27 and $30. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Both analysts lean positive, and no Hold or Sell ratings appear in the verified set. The narrow spread shows agreement on near-term prospects, though the small sample size warrants extra caution.
Current Market Position and Path to the Target
Shares recently closed near $21.19, translating to a market capitalization of roughly $100 million. Reaching the $28.50 average target would mean an advance of about 34%, a sizable gain for any micro-cap name.
That move hinges on continued revenue expansion and movement toward profitability. Trailing revenue stands near $251 million, yet the company posted a net loss and diluted EPS of roughly -$0.89. Trading on the Nasdaq Capital Market with average daily volume in the tens of thousands of shares, price swings can be magnified by thin liquidity.
Factors That Could Drive Shares Higher
- Revenue momentum: Target increases followed the second-quarter report, suggesting results beat expectations.
- Asset-light model: The DRO approach centralizes back-office functions without owning every clinical practice, potentially aiding margin expansion at scale.
- Positive revisions: Two target hikes in the same week point to improving fundamentals and upward estimate changes.
- Limited float: A modest share count can amplify gains if interest builds, though the same trait increases downside volatility.
Risks That Could Keep the Target Out of Reach
- Lack of profitability: Negative EPS and margins mean any valuation support must come from growth expectations rather than current earnings.
- Thin coverage and liquidity: Only two analysts and modest volume make price discovery less efficient and more prone to swings.
- Leverage: A total debt-to-equity ratio above 200% represents a notable balance-sheet factor for a smaller company.
- Valuation compression risk: If growth slows, a stock trading above the midpoint of its 52-week range could see multiples contract quickly.
Technical Levels and Market Structure
Since listing, the stock has ranged from roughly $9.53 to $26.79. The current price sits above the midpoint yet below the high. The $26.79 zone marks key resistance and the prior peak, while $20 and the mid-teens have provided support. The $28.50 target lies above the 52-week high, so reaching it would require a fresh record high since the public debut.
What Investors Should Monitor
Analyst targets typically look out about 12 months, though the exact horizon for these two firms is not specified. Focus on upcoming quarterly results, any guidance updates, new analyst coverage, and trends in patient volume. For a company still early in its public phase, signs of profitability, free cash flow, and debt reduction will matter as much as top-line growth.
Using AI Tools in My Research
In my own research process, I often turn to Tickeron’s AI Daily Buy/Sell Signals to get an additional layer of insight on stocks like this one. It helps flag potential shifts in momentum that might not be obvious from fundamentals alone, especially useful for thinly traded names where automated monitoring can highlight changes more efficiently than manual review.
Final Assessment
Reaching $28.50 would require Park Dental Partners (PARK) to rise roughly 34% from recent levels—a substantial but feasible move. The central target averages two credible, recently updated estimates ($27 and $30) issued after a strong second quarter, giving it a coherent fundamental foundation. The main hurdles remain negative earnings, elevated leverage, very limited analyst coverage, and the fact that the target sits above the 52-week high. The tight $27–$30 range reflects analyst alignment but also a small sample. Investors should watch upcoming earnings, progress toward profitability, and any broadening of coverage before concluding whether the shares can sustain a move toward this level.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
PARK's MACD Histogram crosses above signal line
The Moving Average Convergence Divergence (MACD) for PARK turned positive on October 28, 2026. Looking at past instances where PARK's MACD turned positive, the stock continued to rise in 6 of 6 cases over the following month. The odds of a continued upward trend are 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on November 06, 2026. You may want to consider a long position or call options on PARK as a result. In 13 of 15 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 87%.
PARK moved above its 50-day moving average on November 09, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for PARK crossed bullishly above the 50-day moving average on November 06, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 2 of 3 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 67%.
Following a +5.10% 3-day Advance, the price is estimated to grow further. Considering data from situations where PARK advanced for three days, in 45 of 49 cases, the price rose further within the following month. The odds of a continued upward trend are 90%.
Bearish Trend Analysis
The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where PARK declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 83%.
PARK broke above its upper Bollinger Band on October 30, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for PARK entered a downward trend on October 19, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 13 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.172) is normal, around the industry mean (204.532). P/E Ratio (-26.472) is within average values for comparable stocks, (21.572). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.498). Dividend Yield (0.000) settles around the average of (0.154) among similar stocks. P/S Ratio (0.381) is also within normal values, averaging (2.688).
The Tickeron Price Growth Rating for this company is 46 (best 1 - 100 worst), indicating steady price growth. PARK’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 96 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 99 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. PARK’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 83, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
How to use the Advance/Decline Ratio in trading
How Do You Understand Tax Returns: Importance, Retention, and Deductions?
Revolutionizing Profitable Trading with AI-Driven Trend Forecasting Technology
Week (May 13 - 17) in Review: Financial Leaders
Top Car Company Stocks to Invest in 2024: A Financial Analysis
General Information
Industry HospitalNursingManagement
Advertisement